Orosomucoid-1 Arises as a Shared Altered Protein in Two Models of Multiple Sclerosis.

Ingenuity Pathway Analysis central nervous system (CNS) cortex glia proteomic analysis spinal cord (SC)

Journal

Neuroscience
ISSN: 1873-7544
Titre abrégé: Neuroscience
Pays: United States
ID NLM: 7605074

Informations de publication

Date de publication:
15 Dec 2023
Historique:
received: 28 06 2023
revised: 16 10 2023
accepted: 18 10 2023
pubmed: 11 11 2023
medline: 11 11 2023
entrez: 10 11 2023
Statut: ppublish

Résumé

Multiple sclerosis (MS) is a complex autoimmune and neurodegenerative disorder that affects the central nervous system (CNS). It is characterized by a heterogeneous disease course involving demyelination and inflammation. In this study, we utilized two distinct animal models, cuprizone (CPZ)-induced demyelination and experimental autoimmune encephalomyelitis (EAE), to replicate various aspects of the disease. We aimed to investigate the differential CNS responses by examining the proteomic profiles of EAE mice during the peak disease (15 days post-induction) and cuprizone-fed mice during the acute phase (38 days). Specifically, we focused on two different regions of the CNS: the dorsal cortex (Cx) and the entire spinal cord (SC). Our findings revealed varied glial, synaptic, dendritic, mitochondrial, and inflammatory responses within these regions for each model. Notably, we identified a single protein, Orosomucoid-1 (Orm1), also known as Alpha-1-acid glycoprotein 1 (AGP1), that consistently exhibited alterations in both models and regions. This study provides insights into the similarities and differences in the responses of these regions in two distinct demyelinating models.

Identifiants

pubmed: 37949310
pii: S0306-4522(23)00471-2
doi: 10.1016/j.neuroscience.2023.10.015
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

203-217

Informations de copyright

Copyright © 2023 IBRO. Published by Elsevier Ltd. All rights reserved.

Auteurs

Sonsoles Barriola (S)

Department of Molecular, Cellular and Developmental Neurobiology, Instituto Cajal, Consejo Superior de Investigaciones Científicas-CSIC, Madrid 28002, Spain; Ph.D. Program in Neuroscience, Autónoma de Madrid University-Cajal Institute, Madrid 28029, Spain.

Lina María Delgado-García (LM)

Department of Molecular, Cellular and Developmental Neurobiology, Instituto Cajal, Consejo Superior de Investigaciones Científicas-CSIC, Madrid 28002, Spain; Laboratory of Molecular Neurobiology, Department of Biochemistry, Universidade Federal de São Paulo UNIFESP, São Paulo 04039032, Brazil.

Paz Cartas-Cejudo (P)

Clinical Neuroproteomics Unit, Proteomics Platform, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IDISNA, Pamplona 31008, Spain.

Ignacio Iñigo-Marco (I)

Clinical Neuroproteomics Unit, Proteomics Platform, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IDISNA, Pamplona 31008, Spain.

Joaquín Fernández-Irigoyen (J)

Clinical Neuroproteomics Unit, Proteomics Platform, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IDISNA, Pamplona 31008, Spain.

Enrique Santamaría (E)

Clinical Neuroproteomics Unit, Proteomics Platform, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IDISNA, Pamplona 31008, Spain.

Laura López-Mascaraque (L)

Department of Molecular, Cellular and Developmental Neurobiology, Instituto Cajal, Consejo Superior de Investigaciones Científicas-CSIC, Madrid 28002, Spain. Electronic address: mascaraque@cajal.csic.es.

Classifications MeSH